TREA

97855624 - GALOMIC

Follow

Information

  • Trademark
  • 97855624
  • Serial Number
    97855624
  • Registration Number
    7575494
  • Filing Date
    March 24, 2023
    2 years ago
  • Registration Date
    November 26, 2024
    a year ago
  • Transaction Date
    November 26, 2024
    a year ago
  • Status Date
    November 26, 2024
    a year ago
  • Published for Opposition Date
    October 03, 2023
    2 years ago
  • Location Date
    November 25, 2024
    a year ago
  • Status Code
    700
  • Current Location
    FILE REPOSITORY (FRANCONIA)
    Employee Name
    WOOD, CAROLINE
  • Attorney Docket Number
    210309.00128
    Attorney Name
    Anna King
  • Owners
Information
Mark Drawing Code
4
Mark Identification
GALOMIC
Case File Statements
  • GS0401: Custom manufacture of pharmaceutical and medical preparations for use in targeting genes and blocking, silencing or inhibiting gene expression; custom manufacture of RNAi-based pharmaceuticals and medicines; custom manufacture of short interfering RNA (siRNA) medicines; custom manufacture of nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression; custom manufacture of pharmaceutical and medical preparations for use in targeting messenger RNA (mRNA) and triggering its degradation; provision of information, advice and consultancy services relating to all of the aforesaid
  • GS0091: Downloadable and recorded computer software for use in the field of pharmaceuticals, medicines and drug delivery, namely, for evaluating, analysing, and interpreting information contained in databases to identify new biological targets and gene-disease associations; downloadable and recorded computer software for facilitating the targeted delivery of pharmaceutical and medical preparations; downloadable and recorded computer software for facilitating the targeted delivery of pharmaceutical and medical preparations for silencing or inhibiting gene expression; downloadable and recorded computer software for facilitating the targeted delivery of RNAI-based and short interfering RNA-based (siRNA) medicines and pharmaceuticals, and nucleic acid-based drugs (NABDs); downloadable and recorded computer software using artificial intelligence for machine learning for use in the field of pharmaceuticals, medicines and drug delivery; downloadable and recorded software using artificial intelligence for machine learning for facilitating the delivery of pharmaceutical and medical preparations; downloadable and recorded software using artificial intelligence for machine learning for facilitating the delivery of pharmaceutical and medical preparations targeting genes and silencing or inhibiting gene expression; downloadable and recorded software using artificial intelligence for machine learning for facilitating the delivery of RNAI-based and short interfering RNA-based (siRNA) medicines and pharmaceuticals, and nucleic acid-based drugs (NABDs); downloadable and recorded software using artificial intelligence for machine learning for facilitating the delivery of RNAI-based and short interfering RNA-based (siRNA) medicines and pharmaceuticals, and nucleic acid-based drugs (NABDs), all for targeting genes and silencing or inhibiting gene expression; electronic databases for use in the field of pharmaceuticals, medicines and drug delivery recorded on computer media; electronic databases for use in the field of gene therapy recorded on computer media; electronic databases for use in the field of gene therapy, namely, the delivery of pharmaceutical and medical preparations recorded on computer media; electronic databases for use in the field of gene therapy, namely, the delivery of pharmaceutical and medical preparations targeting and silencing or inhibiting of genes recorded on computer media; electronic databases for use in the field of gene therapy, namely, the delivery of RNAI-based and short interfering RNA-based (siRNA) medicines and pharmaceuticals, and nucleic acid-based drugs (NABDs) recorded on computer media; downloadable and recorded computer platform software for use in the field of pharmaceuticals, medicines and drug delivery, namely, for evaluating, analysing, and interpreting information contained in databases to identify new biological targets and gene-disease associations; downloadable and recorded computer software platforms for use in the field of pharmaceuticals, medicines and drug delivery, namely, for evaluating, analysing, and interpreting information contained in databases to identify new biological targets and gene-disease associations; downloadable and recorded computer software for enabling the searching and retrieval of data relating to pharmaceuticals, medicines and drug discovery; downloadable and recorded software for the analysis of data relating to pharmaceuticals, medicines and drug discovery; downloadable and recorded search engine software for use in the field of pharmaceuticals, medicines and drug discovery; downloadable and recorded search engine software for the searching, retrieval, indexing and analysis of data relating to pharmaceuticals, medicines and drug discovery
  • GS0051: Pharmaceutical and medical preparations for use in targeting genes and silencing or inhibiting gene expression; drug delivery agents that facilitate the delivery of pharmaceutical preparations targeting genes and silencing or inhibiting gene expression; drug delivery agents that facilitate the delivery of RNAI-based and short interfering RNA-based (siRNA) medicines and pharmaceuticals, and nucleic acid-based drugs (NABDs); drug delivery agents that facilitate the delivery of RNAI-based and short interfering RNA-based (siRNA) medicines and pharmaceuticals, and nucleic acid-based drugs (NABDs), all for targeting genes and silencing or inhibiting gene expression; RNAi-based medicines and pharmaceuticals for use in targeting genes and blocking, silencing, or inhibiting gene expression, and for use in targeting mRNA and triggering its degradation; short interfering RNA-based (siRNA) medicines and pharmaceuticals for use in targeting genes and blocking, silencing, or inhibiting gene expression, and for use in targeting mRNA and triggering its degradation; nucleic acid-based drugs (NABDs) for use in targeting genes and blocking, silencing, or inhibiting gene expression, and for use in targeting mRNA and triggering its degradation; pharmaceutical and medical preparations for use in targeting messenger RNA (mRNA) and triggering its degradation
  • GS0421: Scientific research and development in the field of targeting genes and blocking, silencing or inhibiting gene expression; scientific, pharmaceutical and medical research and development services relating to RNAi-based pharmaceuticals and medicines; scientific, pharmaceutical and medical research and development services relating to pharmaceutical and medical preparations for use in targeting genes and blocking, silencing or inhibiting gene expression; scientific, pharmaceutical and medical research and development services relating to short interfering RNA (siRNA) medicines, nucleic acid-based drugs (NABDs) for blocking gene expression, nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression, and, pharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation; drug discovery services relating to RNAi-based pharmaceuticals and medicines; drug discovery services relating to pharmaceutical and medical preparations for use in targeting genes and blocking, silencing or inhibiting gene expression; drug discovery services relating to short interfering RNA (siRNA) medicines, nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression, and pharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation; scientific and technical data analysis in relation to pharmaceuticals and medicines; scientific and technical data analysis in relation to RNAi-based medicines; scientific and technical data analysis in relation to pharmaceutical and medical preparations for use in targeting genes and blocking, silencing or inhibiting gene expression; scientific and technical data analysis in relation to short interfering RNA (siRNA) medicines, nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression, and pharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation; design, development, creation and maintenance of computer platforms and computer software for use in the field of pharmaceuticals, medicines and drug discovery; design, development, creation and maintenance of computer platforms and computer software enabling the searching and retrieval of data relating to pharmaceuticals, medicines and drug discovery; design, development, creation and maintenance of computer platforms and computer software for the analysis of data relating to pharmaceuticals, medicines and drug discovery; design of and providing temporary use of online non-downloadable search engine software for use in the field of pharmaceuticals, medicines and drug discovery; design of and providing temporary use of online non-downloadable search engine software for the searching, retrieval, indexing and analysis of data relating to pharmaceuticals, medicines and drug discovery; Platform as a Service (PaaS) services featuring computer software platforms using artificial intelligence and machine learning software and databases for modelling genetic sequences and gene-disease associations, and for identifying and ranking potential gene targets, and for generating pharmaceutical and medical preparations all for use in the fields of pharmaceuticals, medicines and drug discovery; Platform as a Service (PaaS) services featuring computer software platforms using artificial intelligence and machine learning software and databases for modelling genetic sequences and gene-disease associations, and for identifying and ranking potential gene targets, and for generating RNAi-based medicines and pharmaceuticals, short interfering RNA (siRNA) medicines, nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression, and pharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation, all for use in the fields of pharmaceuticals, medicines, and drug discovery; design and development of computer-simulated models for use in the field of pharmaceuticals, medicines and drug discovery; providing temporary use of online non-downloadable computer software for evaluating, analysing, and interpreting information contained in databases to identify new biological targets and gene-disease associations, all for use in the field of pharmaceuticals, medicines and drug delivery; providing temporary use of online non-downloadable computer software for facilitating the targeted delivery of pharmaceutical and medical preparations, all for use in the field of pharmaceuticals, medicines and drug delivery; providing temporary use of online non-downloadable computer software for facilitating the targeted delivery of pharmaceutical and medical preparations for silencing or inhibiting gene expression, all for use in the field of pharmaceuticals, medicines and drug delivery; providing temporary use of online non-downloadable computer software for facilitating the targeted delivery of RNAI-based and short interfering RNA-based (siRNA) medicines and pharmaceuticals, and nucleic acid-based drugs (NABDs), all for use in the field of pharmaceuticals, medicines and drug delivery; providing temporary use of online non-downloadable computer for machine learning for use in the field of pharmaceuticals, medicines and drug delivery; providing temporary use of online non-downloadable computer software using artificial intelligence for machine learning for facilitating the delivery of pharmaceutical and medical preparations, all for use in the field of pharmaceuticals, medicines and drug delivery; providing temporary use of online non-downloadable computer software using artificial intelligence for machine learning for facilitating the delivery of pharmaceutical and medical preparations targeting genes and silencing or inhibiting gene expression, all for use in the field of pharmaceuticals, medicines and drug delivery; providing temporary use of online non-downloadable computer software using artificial intelligence for machine learning for facilitating the delivery of RNAI-based and short interfering RNA-based (siRNA) medicines and pharmaceuticals, and nucleic acid-based drugs (NABDs), all for use in the field of pharmaceuticals, medicines and drug delivery; providing temporary use of online non-downloadable computer software using artificial intelligence for machine learning for facilitating the delivery of RNAI-based and short interfering RNA-based (siRNA) medicines and pharmaceuticals, and nucleic acid-based drugs (NABDs), all for targeting genes and silencing or inhibiting gene expression, all for use in the field of pharmaceuticals, medicines and drug delivery; Software as a Service (SaaS) services featuring software using artificial intelligence and machine learning software for modelling genetic sequences and gene-disease associations, and for identifying and ranking potential gene targets, and for generating pharmaceutical and medical preparations databases all in the field of pharmaceuticals, medicines and drug discovery; Software as a Service (SaaS) services featuring software using artificial intelligence and machine learning for modelling genetic sequences and gene-disease associations, and for identifying and ranking potential gene targets, and for generating RNAi-based medicines and pharmaceuticals, nucleic acid-based drugs (NABDs) for blocking, silencing or inhibiting gene expression, and pharmaceutical and medical preparations for use in targeting mRNA and triggering its degradation, all for use in the fields of pharmaceuticals, medicines and drug discovery; provision of information, advice and consultancy services relating to all of the aforesaid
Case File Event Statements
  • 3/28/2023 - 2 years ago
    1 - NEW APPLICATION ENTERED Type: NWAP
  • 4/16/2023 - 2 years ago
    2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS
  • 4/25/2023 - 2 years ago
    3 - ASSIGNED TO EXAMINER Type: DOCK
  • 4/27/2023 - 2 years ago
    4 - NON-FINAL ACTION WRITTEN Type: CNRT
  • 4/27/2023 - 2 years ago
    5 - NON-FINAL ACTION E-MAILED Type: GNRT
  • 4/27/2023 - 2 years ago
    6 - NOTIFICATION OF NON-FINAL ACTION E-MAILED Type: GNRN
  • 7/24/2023 - 2 years ago
    7 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA
  • 7/24/2023 - 2 years ago
    8 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 7/24/2023 - 2 years ago
    9 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 8/1/2023 - 2 years ago
    10 - TEAS VOLUNTARY AMENDMENT RECEIVED Type: PARI
  • 8/29/2023 - 2 years ago
    11 - EXAMINERS AMENDMENT -WRITTEN Type: CNEA
  • 8/29/2023 - 2 years ago
    12 - EXAMINERS AMENDMENT E-MAILED Type: GNEA
  • 8/29/2023 - 2 years ago
    13 - NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Type: GNEN
  • 8/29/2023 - 2 years ago
    14 - EXAMINER'S AMENDMENT ENTERED Type: XAEC
  • 8/31/2023 - 2 years ago
    15 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA
  • 9/13/2023 - 2 years ago
    16 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP
  • 10/3/2023 - 2 years ago
    17 - PUBLISHED FOR OPPOSITION Type: PUBO
  • 10/3/2023 - 2 years ago
    18 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB
  • 11/28/2023 - 2 years ago
    19 - NOA E-MAILED - SOU REQUIRED FROM APPLICANT Type: NOAM
  • 4/29/2024 - a year ago
    20 - SOU TEAS EXTENSION RECEIVED Type: EEXT
  • 4/29/2024 - a year ago
    21 - SOU EXTENSION 1 FILED Type: EXT1
  • 4/29/2024 - a year ago
    22 - SOU EXTENSION 1 GRANTED Type: EX1G
  • 4/30/2024 - a year ago
    23 - NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Type: EXRA
  • 11/4/2024 - a year ago
    25 - NOTICE OF ALLOWANCE CANCELLED Type: IUCN
  • 11/4/2024 - a year ago
    24 - TEAS DELETE 1(B) BASIS RECEIVED Type: D1BR
  • 11/5/2024 - a year ago
    26 - 1(B) BASIS DELETED; PROCEED TO REGISTRATION Type: DP1B
  • 11/26/2024 - a year ago
    27 - REGISTERED-PRINCIPAL REGISTER Type: R.PR
  • 11/26/2024 - a year ago
    28 - NOTICE OF REGISTRATION CONFIRMATION EMAILED Type: NRCC